Zegocractin - CalciMedica
Alternative Names: Auxora; CM-4620; CM4620-IELatest Information Update: 03 Jul 2024
At a glance
- Originator CalciMedica
- Class Anti-inflammatories; Antivirals; Benzamides; Chlorobenzenes; Dioxoles; Fluorobenzenes; Pyrazines; Small molecules; Urologics
- Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID-19 pneumonia
- Phase II Acute kidney injury; Pancreatitis; SARS-CoV-2 acute respiratory disease; Systemic inflammatory response syndrome
- Preclinical Inflammatory bowel diseases; Renal failure; Respiratory distress syndrome
Most Recent Events
- 27 Jun 2024 CalciMedica plans end-of-phase II meeting with the FDA in preparation for a pivotal trial
- 27 Jun 2024 Efficacy and adverse events data from a phase II trial in Pancreatitis released by CalciMedica
- 26 Jun 2024 CalciMedica completes a phase II CARPO tiral in Systemic inflammatory response syndrome and Pancreatitis in India, USA (IV) (NCT04681066)